Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer
Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety, tolerability, and anti-tumor activity in separate cohorts of subjects with HER2+ BC, […]